TriSalus Life Sciences: Continuing To Maintain Optimism As Costs Are Cut
TLSI's posted a net loss of $2.4 million for the quarter, but management is optimistic about turning cash flow positive by ...
pharmaphorum2 天
Long-acting injectables for biologics: Current landscape and future perspective
The microspheres are made using double emulsion ... and do not induce acidic pH microenvironment will greatly benefit commercial LAIs, also. While developing in situ forming depots, future ...